2012 financial year: Bachem clearly tops prior-year results at all levels

March 15, 2013
  • Healthy top-line growth of 7.9%
  • EBIT up sharply to 22.0 million CHF (+48.4%)
  • Margins of 28.2% (EBITDA) and 14.0% (EBIT)
  • Disproportionate bottom-line growth to 15.3 million CHF (+62.6%)
  • Strong business with NCEs, research chemicals still under pressure, improved results from generic peptides
  • Steady growth in sales and profits forecast


At Bachem, we believe that our employees make the difference. Representing our corporate culture of passion and commitment, they are the foundation of our success. We therefore strive to attract, retain, and develop highly motivated, well-qualified individuals.

View all jobs

Click here >>

Contact us


  • Fields marked with an asterisk (*) are required

  • Hidden
  • Hidden
  • This field is for validation purposes and should be left unchanged.